These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1055 related articles for article (PubMed ID: 29548607)

  • 21. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant.
    Ferguson M; Risi G; Davis M; Sheldon E; Baron M; Li P; Madariaga M; Fries L; Godeaux O; Vaughn D
    J Infect Dis; 2012 Mar; 205(5):733-44. PubMed ID: 22315336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
    Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
    Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Age-associated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1.
    Jegaskanda S; Laurie KL; Amarasena TH; Winnall WR; Kramski M; De Rose R; Barr IG; Brooks AG; Reading PC; Kent SJ
    J Infect Dis; 2013 Oct; 208(7):1051-61. PubMed ID: 23812238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination.
    Sangster MY; Baer J; Santiago FW; Fitzgerald T; Ilyushina NA; Sundararajan A; Henn AD; Krammer F; Yang H; Luke CJ; Zand MS; Wright PF; Treanor JJ; Topham DJ; Subbarao K
    Clin Vaccine Immunol; 2013 Jun; 20(6):867-76. PubMed ID: 23576673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccination with 2014-15 Seasonal Inactivated Influenza Vaccine Elicits Cross-Reactive Anti-HA Antibodies with Strong ADCC Against Antigenically Drifted Circulating H3N2 Virus in Humans.
    Zhong W; Gross FL; Holiday C; Jefferson SN; Bai Y; Liu F; Katz JM; Levine MZ
    Viral Immunol; 2016 May; 29(4):259-62. PubMed ID: 26950058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging influenza viruses.
    Jegaskanda S; Vandenberg K; Laurie KL; Loh L; Kramski M; Winnall WR; Kedzierska K; Rockman S; Kent SJ
    J Infect Dis; 2014 Dec; 210(11):1811-22. PubMed ID: 24916185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
    Roman F; Vaman T; Gerlach B; Markendorf A; Gillard P; Devaster JM
    Vaccine; 2010 Feb; 28(7):1740-5. PubMed ID: 20034605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A live attenuated H5N2 prime- inactivated H5N1 boost vaccination induces influenza virus hemagglutinin stalk specific antibody responses.
    Kongchanagul A; Samnuan K; Wirachwong P; Surichan S; Puthavathana P; Pitisuttithum P; Boonnak K
    Vaccine; 2020 Jan; 38(4):852-858. PubMed ID: 31708176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody responses against influenza A(H1N1)pdm09 virus after sequential vaccination with pandemic and seasonal influenza vaccines in Finnish healthcare professionals.
    Strengell M; Ikonen N; Ziegler T; Kantele A; Anttila VJ; Julkunen I
    Influenza Other Respir Viruses; 2013 May; 7(3):431-8. PubMed ID: 22913369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies.
    Garcia-Sicilia J; Arístegui J; Omeñaca F; Carmona A; Tejedor JC; Merino JM; García-Corbeira P; Walravens K; Bambure V; Moris P; Caplanusi A; Gillard P; Dieussaert I
    Hum Vaccin Immunother; 2015; 11(10):2359-69. PubMed ID: 26176592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of Influenza Vaccines: Evidence for Differential Effect of Secondary Vaccination on Humoral and Cellular Immunity.
    Rosendahl Huber SK; Hendriks M; Jacobi RHJ; van de Kassteele J; Mandersloot-Oskam JC; van Boxtel RAJ; Wensing AMJ; Rots NY; Luytjes W; van Beek J
    Front Immunol; 2018; 9():3103. PubMed ID: 30761157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.
    Desheva YA; Smolonogina TA; Donina SA; Rudenko LG
    BMC Res Notes; 2015 Apr; 8():136. PubMed ID: 25889924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.
    Florek KR; Weinfurter JT; Jegaskanda S; Brewoo JN; Powell TD; Young GR; Das SC; Hatta M; Broman KW; Hungnes O; Dudman SG; Kawaoka Y; Kent SJ; Stinchcomb DT; Osorio JE; Friedrich TC
    J Virol; 2014 Nov; 88(22):13418-28. PubMed ID: 25210172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older.
    Van Damme P; Kafeja F; Bambure V; Hanon E; Moris P; Roman F; Gillard P
    Hum Vaccin Immunother; 2013 Jul; 9(7):1512-22. PubMed ID: 23571166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers.
    Hsu JP; Phoon MC; Koh GC; Chen MI; Lee VJ; Wu Y; Xie ML; Cheong A; Leo YS; Chow VT
    Int J Infect Dis; 2012 Aug; 16(8):e621-7. PubMed ID: 22704721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials.
    Roman F; Clément F; Dewé W; Walravens K; Maes C; Willekens J; De Boever F; Hanon E; Leroux-Roels G
    Clin Vaccine Immunol; 2011 May; 18(5):835-43. PubMed ID: 21450978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.
    Li GM; Chiu C; Wrammert J; McCausland M; Andrews SF; Zheng NY; Lee JH; Huang M; Qu X; Edupuganti S; Mulligan M; Das SR; Yewdell JW; Mehta AK; Wilson PC; Ahmed R
    Proc Natl Acad Sci U S A; 2012 Jun; 109(23):9047-52. PubMed ID: 22615367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.
    Carmona A; Omeñaca F; Tejedor JC; Merino JM; Vaman T; Dieussaert I; Gillard P; Arístegui J
    Vaccine; 2010 Aug; 28(36):5837-44. PubMed ID: 20600478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Seasonal influenza vaccines induced high levels of neutralizing cross-reactive antibody responses against different genetic group influenza A(H1N1)pdm09 viruses.
    Haveri A; Ikonen N; Kantele A; Anttila VJ; Ruotsalainen E; Savolainen-Kopra C; Julkunen I
    Vaccine; 2019 May; 37(20):2731-2740. PubMed ID: 30954308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.